The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Learn more about AbbVie’s response to COVID-19

VIDEO LIBRARY

SEE WHAT YOUR PEERS ARE SAYING ABOUT SKYRIZI

SKYRIZI IN BIO-NAÏVE PATIENTS

Dr. Schwartzman and Dr. Khattri define how a bio-naïve patient may present in clinical practice and review the demographics of the patient population evaluated in the KEEPsAKE 1 PsA trial.

EFFICACY & SAFETY RESULTS WITH SKYRIZI

Dr. Schwartzman and Dr. Khattri review the clinical efficacy endpoints from the PsA trials, including ACR20/50/70, ACR components such as patient-reported pain, and enthesitis and dactylitis, then conclude with a discussion of SKYRIZI's safety profile across 2 indications.


EXCEPTIONAL PATIENT ACCESS & SUPPORT

For your patients with PsA

Savings Card Icon.

4 DOSES PER YEAR

4 doses per year after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1

Calendar Icon.